The Digest’s 2025 Multi-Slide Guide to Twist Bioscience

Twist Bioscience aims for $1 billion in revenue and is crossing the threshold to Adjusted EBITDA breakeven, reporting Q2 FY2025 revenue of $92.8M. The company emphasizes continued product innovation, including mRNA and milligram scale plasmid, and enzymology capabilities for higher margins and differentiation. With capacity in place and low variable costs, they are poised for significant volume and margin expansion, driving shareholder value in synthetic biology.